2008
DOI: 10.1002/ijc.23718
|View full text |Cite
|
Sign up to set email alerts
|

Combination regimen with statins and NSAIDs: A promising strategy for cancer chemoprevention

Abstract: Statins and nonsteroidal antiinflammatory drugs (NSAIDs) are commonly prescribed for lowering cholesterol and antiinflammation, respectively. Recently, their potential roles as cancer chemopreventive agents have been subject to intensive studies. Human trials have not provided conclusive results on the protective effects of statins against different cancers, while more convincing results have been observed for cancer preventive effects of NSAIDs, especially on colorectal cancer. A promising strategy to enhance… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
69
1

Year Published

2011
2011
2017
2017

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 84 publications
(70 citation statements)
references
References 95 publications
0
69
1
Order By: Relevance
“…Simvastatin has been used in combination therapy with several chemotherapeutic agents/targeted therapies such as farnesyl transferase inhibitors, EGFR inhibitors geftinib and cetuximab, doxorubicin, non-steroidal anti-inflammatory drugs, and vitamin-E gamma tocotrienol in diverse tumor cell lines and in vivo cancer models [10,13,16,[32][33][34] but so far its effects either alone or in combination with anticancer therapies in gastric cancer mouse models has never been studied before. Recently conducted couple of populationbased case-control studies clearly indicate that statins uptake can reduce the risk of gastric cancer [35], and our findings provide further scientific evidence that simvastatin has significant potential for the treatment of gastric cancer and its effects can be further enhanced by capecitabine.…”
Section: Discussionmentioning
confidence: 99%
“…Simvastatin has been used in combination therapy with several chemotherapeutic agents/targeted therapies such as farnesyl transferase inhibitors, EGFR inhibitors geftinib and cetuximab, doxorubicin, non-steroidal anti-inflammatory drugs, and vitamin-E gamma tocotrienol in diverse tumor cell lines and in vivo cancer models [10,13,16,[32][33][34] but so far its effects either alone or in combination with anticancer therapies in gastric cancer mouse models has never been studied before. Recently conducted couple of populationbased case-control studies clearly indicate that statins uptake can reduce the risk of gastric cancer [35], and our findings provide further scientific evidence that simvastatin has significant potential for the treatment of gastric cancer and its effects can be further enhanced by capecitabine.…”
Section: Discussionmentioning
confidence: 99%
“…In azoxymethane induced colon carcinogenesis rat model, the low dose combination of atorvastatin and celecoxib decreased the incidence of adenocarcinomas by 71% [61]. Atorvastatin combination with celecoxib decreased the membrane association of RhoA [58,62]. Here, atorvastatin is preventing the prenylation of RhoA and celecoxib is synergizing the effect and causing cell cycle arrest.…”
Section: Statins With Nsaidsmentioning
confidence: 96%
“…This combination reduced the risk of colorectal cancer by 62% if used for 5 or more years [58]. Moreover, NSAIDS with statins also lowers the risk of prostate cancer if used for 5 years [59].…”
Section: Statins With Nsaidsmentioning
confidence: 98%
See 1 more Smart Citation
“…It is expressed at elevated levels in many cancers, including lung and head and neck (17,18). Celecoxib is a selective COX-2 inhibitor that inhibits synthesis of PGE 2 and has been used in multiple clinical chemoprevention studies (19). E6 and E7 are early genes that are not only essential to the viral lifecycle, but code for the proteins most implicated in HPV-induced carcinogenesis (20,21).…”
Section: Cox-2 Activity and Hpv Transcriptionmentioning
confidence: 99%